Extended OC use may relieve PMS

Article

Taking a continuous 168-day course of oral contraceptives (OCs) can reduce symptoms of premenstrual syndrome, or PMS, compared to the 21/7-day regimen, according to the results of a study published in the November issue of the American Journal of Obstetrics and Gynecology.

Taking a continuous 168-day course of oral contraceptives (OCs) can reduce symptoms of premenstrual syndrome, or PMS, compared to the 21/7-day regimen, according to the results of a study published in the November issue of the American Journal of Obstetrics and Gynecology.

Andrea L. Coffee, PharmD, of Scott & White Memorial Hospital in Temple, Tex., and colleagues conducted a study of 111 women who had switched from a 21/7-day regimen of an OC containing 3 mg of drosperinone and 30 μg of ethinylestradiol to a continuous 168-day regimen.

A subgroup of 55 women (54%) with the greatest cyclical variation in physical symptoms and mood swings was identified and taken to resemble patients with premenstrual syndrome. Those women who experienced the most severe cyclic variability when taking the OCs on a 21/7-day basis benefited the most from a 168-day regimen, with the biggest improvement noted during the 6th month.

Coffee AL, Kuehl TJ, Willis S, et al. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol. 2006;195:1311-1319.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
Related Content
© 2024 MJH Life Sciences

All rights reserved.